ArticleESMO open2026

Real-world postprogression outcomes after first-line treatment with ribociclib plus aromatase inhibitor versus aromatase inhibitor alone in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in the United States of America.

L Hart et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.